Adagene Inc.

What they do

Adagene is a Cayman Islands-incorporated, China-based biopharmaceutical company focused on discovering and developing novel antibody therapeutics. It operates through its PRC subsidiary Adagene (Suzhou) Limited and a U.S. subsidiary. The company uses its proprietary NEObody and SAFEbody platforms to design antibodies with novel mechanisms of action, including bispecific T-cell engagers and antibody-drug conjugates. Its lead programs target immuno-oncology indications.

Revenue drivers

• Collaboration and license agreements — Revenue primarily comes from upfront payments, milestone payments, and royalties under partnerships. Annual revenue fluctuated significantly: $18.1M in 2023, $0.1M in 2024, and $7.7M in 2025.

Recent performance

In 2025, Adagene reported annual revenue of $7.7 million, down from $0.1 million in 2024 and $18.1 million in 2023. Net loss narrowed to $17.6 million from $33.4 million in 2024, and diluted EPS improved to -$0.30 from -$0.59. Operating cash outflow also decreased to -$15.7 million from -$29.7 million in the prior year. The balance sheet at year-end showed total assets of $78.3 million and cash and equivalents of $74.5 million.

Strategy

The company is advancing its NEObody and SAFEbody technology platforms to create next-generation antibody therapies. It continues to invest in R&D, with a focus on immuno-oncology and bispecific programs. Management has not disclosed specific new collaborations or product launches in the provided excerpt. The company aims to leverage its platforms to attract partnerships and progress its pipeline toward clinical milestones.

Risks

• Dependence on collaborations — Revenue is highly dependent on partnership payments, and the volatility (from $18.1M in 2023 to $0.1M in 2024) shows vulnerability to deal timing.
• Clinical-stage pipeline — The company has no approved products, and all potential revenue depends on successful clinical development, which is uncertain.
• Limited cash runway — With $74.5 million in cash and annual burn of about $15.7 million in operating cash flow, the company may need additional funding to support long-term operations.
• Regulatory and geopolitical exposure — Operations and clinical trials are largely in China, subject to local regulatory, legal, and geopolitical risks.

Outlook

Management does not provide explicit forward-looking statements in the excerpt. The company expects to continue advancing its pipeline, but revenue levels will depend on achieving clinical milestones and securing new collaborations. With diminishing losses, the company is focusing on operational efficiency while developing its platforms.